



Colorado Institute for Drug, Device and Diagnostic Development (CID4) Announces New Executive Director

MEDIA ADVISORY: For Immediate Release

CONTACTS:

Jonathan Thorne
Chairman, CID4 Board of Directors
Email: jthorne@epsurgical.com
Ph: (303) 877-9767

Ginny Orndorff
Executive Director, CID4
Email: ginny.orndorff@CID4.com
Ph: (303) 638-3521

Aurora, CO – February 17, 2015 - Ginny Orndorff, MA, MBA, has been named as the new Executive Director for the Colorado Institute for Drug, Device and Diagnostic Discovery (CID4), following the retirement of Kevin Smith. The CID4 is a nonprofit commercial innovation accelerator supported by the Colorado Office of Economic Development and International Trade. The selection was made after a national search and selection process conducted by an ad hoc committee made up of CID4 Board Members. Acting CID4 Board Chairman, Jonathan Thorne, said, "We are very pleased to announce this appointment. Ginny will bring leadership and ingenuity to the CID4 programs, along with a deep sense of commitment to Colorado's bioscience community. She is a serial entrepreneur with experience in all aspects of bioscience start-ups."

Ginny's resume includes over 30 years of bioscience company management. She received a Bachelor's Degree in Biology from the University of California Santa Cruz, a Master's Degree in Microbiology from California State University San Jose, and an MBA from Loyola College. She has recently been mentoring two University of Colorado Anschutz Medical Campus spin-off companies; SixOne Solutions and Claudin Technologies. Previously, Ginny was a founder and CEO of Evolutionary Genomics of Longmont, CO. Prior to that, she was CEO of GenoPlex of Denver, CO. She also served as Director of Technology/Business Development for NeXstar of Boulder, CO, and Director of Biotechnology Programs at the Colorado Advanced Technology Institute. Ginny began her bioscience career as a lab supervisor at Genex in Gaithersburg, MD.

"CID4 has played an important role in helping high-potential entrepreneurial bioscience companies through early-stage challenges, strengthening their foundation, and positioning them to grow and thrive," Ginny commented. She continued, "Colorado's research institutions garner over \$600 million in federal funds for top-notch bioscience research. This provides a rich resource for entrepreneurs throughout the state to develop ground-breaking products to fill important medical needs and enhance Colorado's economy. I look forward to continuing to build CID4's capabilities and impact."

“I am truly excited to have Ginny on board,” said CID4 Founder and Chief Scientific Officer, Dr. Richard Duke. “The companies, technology and entrepreneurs that we work with at CID4 are typically at a very early stage. It’s critical to have an Executive Director who understands the needs of those early stage companies and who possesses the requisite experience to mentor and guide the entrepreneurs while the companies are just starting to take shape.” Duke went on to say, “Ginny’s management style is especially well-suited for mentoring. I think we are extremely fortunate to have Ginny leading our organization at this point.”

About the Colorado Institute for Drug Device and Diagnostic Development

The Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a nonprofit commercial innovation accelerator supported by the Colorado Office of Economic Development and International Trade. Assisted by a high-caliber Technology and Business Advisory Committee, CID4 selects high-potential entrepreneurial Colorado bioscience companies for seed investment and business/technical mentoring. Portfolio companies include Sophono (*hearing device*), PeptiVir (*rapidly deployable vaccine technology for influenza and other viruses*), VetDC (*companion animal cancer drugs*), Flashback Technologies (*CipherSensorTM for rapid analysis of patient data in critical care settings*), KromaTiD (*novel technology for detecting genetic diseases for personalized medicine for diseases including cancers and developmental disorders*), Aurora Oncology (*bladder cancer therapeutics and imaging technology*), AkitVax (*custom, pre-filled drug delivery devices*), FitBionic (*prosthetics*) and Sapphire Technologies (*advanced dental tools*).